Clinical Trials Logo

Solid Tumors clinical trials

View clinical trials related to Solid Tumors.

Filter by:

NCT ID: NCT01574235 Completed - Solid Tumors Clinical Trials

Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents

Start date: October 2011
Phase: N/A
Study type: Observational

The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.

NCT ID: NCT01570296 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR

BKM120
Start date: October 3, 2011
Phase: Phase 1
Study type: Interventional

The safety, tolerability and recommended phase 2 dose (RP2D) of the combination of gefitinib and BKM120 will be determined.

NCT ID: NCT01556789 Completed - Solid Tumors Clinical Trials

Phase 1 Study of ONT-10 in Patients With Solid Tumors

Start date: March 2013
Phase: Phase 1
Study type: Interventional

Open label, two part, Phase 1 dose escalation study to evaluate the safety and immunogenicity of repeat dose vaccination with ONT-10 in patients with previously treated Stage 3 or 4 solid tumors. Part 1 to evaluate escalating dose levels of ONT-10 administered subcutaneously every two weeks (Q2W) or weekly (QW) over 8 weeks. Part 2 evaluates the safety, immunogenicity, and potential anti-tumor activity of ONT-10 administered over 8 weeks at the Q2W and QW maximum tolerated does/recommended dose (MTD/RD) in cohorts of 15 patients each.

NCT ID: NCT01553656 Completed - Cancer Clinical Trials

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Start date: February 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese patients with advanced or metastatic solid tumors. Also, the effect of XL184 in the treatment of non-small cell lung cancer (NSCLC) patients with various activating mutations will be evaluated at the recommended Phase 2 dose.

NCT ID: NCT01544322 Completed - Solid Tumors Clinical Trials

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

ME-344-001
Start date: May 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.

NCT ID: NCT01538563 Completed - Cancer Clinical Trials

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Start date: June 2006
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the highest dose of ON 01910.Na that can be safely given as an intravenous infusion over 24 hours once a week in a 3-week cycle to patients with advanced solid tumors.

NCT ID: NCT01538537 Completed - Cancer Clinical Trials

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the largest dose of ON 01910.Na (rigosertib sodium) that can be given safely as a 3-day continuous infusion once every 2 weeks (2-week cycle) in patients with advanced cancer.

NCT ID: NCT01537744 Completed - Solid Tumors Clinical Trials

A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma

Start date: February 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether 5-azacitidine in combination with romidepsin cancer are effective in the treatment of advanced solid tumors.

NCT ID: NCT01532011 Completed - Solid Tumors Clinical Trials

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Start date: March 2012
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the combination of erlotinib and pralatrexate that can be given to patients with advanced cancer. The safety of the drug combination will also be studied. Pralatrexate is designed to block the body's ability to make folic acid, a protein that may help cancer tissue to develop and spread. Erlotinib hydrochloride is designed to block proteins that are thought to cause cancer cells to grow. Erlotinib may help slow the growth of tumors.

NCT ID: NCT01528046 Completed - Solid Tumors Clinical Trials

Metformin in Children With Relapsed or Refractory Solid Tumors

Start date: September 24, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the tolerability and safety of escalating doses of metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with recurrent and refractory solid tumors.